








Pipeline

	Indication/Target	Program	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Trial Name / Collaborator	
Late stage	NSCLC (2 nd /3 rd line)	Plinabulin + Docetaxel	▶						Study 103 (DUBLIN-3) - Presented at ISLAC, ESMO 2024 Published in "LANCET Respiratory Medicine" 09/2024
	CIN Prevention	Plinabulin + Pegfilgrastim	▶						Studies 105 & 106 (PROTECTIVE-1 & PROTECTIVE-2)
Investigator Initiated Trials	ES-SCLC (2 nd /3 rd line)	Plinabulin + Nivolumab + Ipilimumab	▶						Presented at SITC 2023 
	NSCLC (2 nd /3 rd line PD-1/L1 progressed)	Plinabulin + Pembrolizumab + Docetaxel	▶						Study 303 Presented at ESMO 2024, SITC 2024 
	ES-SCLC (1 st line)	Plinabulin + Pembrolizumab + Etoposide / Platinum	▶						Study 302 
	Multiple cancers (PD-1/PD-L1 failed)	Plinabulin + PD-1/PD-L1 + Radiation	▶						Presented at SITC 2023 
Early Stage	Preclinical assets	BPI-002, BPI-003, BPI-004	▶						
SEED	9 Targets in Oncology, Neurodegeneration, Immunology and Antiviral	Targeted Protein Degradation Molecular Glue Platform	▶					  	

1) Dalian Wanchunbulin Pharmaceuticals Ltd., a BeyondSpring subsidiary, owns Greater China rights to Plinabulin

2) BeyondSpring is an equity investor of SEED Therapeutics, a targeted protein degradation company